Sep 21, 2021 / 01:00PM GMT
Manuela Bader - Vivoryon Therapeutics N.V. - Director, IR & Communication
Good afternoon, and thank you for joining us today for Vivoryon's conference call to discuss the Company's first-half 2021 results and operational progress. This morning, Vivoryon issued a press release, which is posted on the Company's website at www.vivoryon.com.
On the call with me today are Ulrich Dauer, Chief Executive Officer of Vivoryon; and Florian Schmid, our Chief Financial Officer. Also with us on today's call and available for questions is Michael Schaeffer, our Chief Business Officer.
We will begin today's call with an opening remark from Ulrich on our strategic focus and focus during the first half, and then Florian will review the financial results. Following the prepared remarks, we will host a Q&A session.
Before we start, I would like to remind you that during this conference call, we will present and discuss certain forward-looking statements concerning the development of Vivoryon Therapeutics' core technology, the
Q2 2021 Vivoryon Therapeutics NV Earnings Call Transcript
Sep 21, 2021
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers